240 related articles for article (PubMed ID: 26900991)
1. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
Rea F; Potena L; Yonan N; Wagner F; Calabrese F
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S19-26. PubMed ID: 26900991
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
3. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
[TBL] [Abstract][Full Text] [Related]
4. The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.
Carbone J
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S11-8. PubMed ID: 26900990
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
8. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
Solidoro P; Patrucco F; Libertucci D; Verri G; Sidoti F; Curtoni A; Boffini M; Simonato E; Rinaldi M; Cavallo R; Costa C
Ther Adv Respir Dis; 2019; 13():1753466619878555. PubMed ID: 31566097
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
[TBL] [Abstract][Full Text] [Related]
10. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
13. The use of CMVIg rescue therapy in cardiothoracic transplantation: A single-center experience over 6 years (2011-2017).
Santhanakrishnan K; Yonan N; Callan P; Karimi E; Al-Aloul M; Venkateswaran R
Clin Transplant; 2019 Aug; 33(8):e13655. PubMed ID: 31251425
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rubin RH; Dienstag JL; Rohrer RH; Freeman R; Jenkins R; Lewis WD; Hammer S; O'Rourke E; Grady GF; Fawaz K; Kaplan MM; Hoffman MA; Katz AT; Doran M;
Ann Intern Med; 1993 Nov; 119(10):984-91. PubMed ID: 8214995
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant.
Kervan U; Kucuker SA; Kocabeyoglu SS; Unal EU; Ozatik MA; Sert DE; Kavasoglu K; Tezer AY; Pac M
Exp Clin Transplant; 2016 Oct; 14(5):551-554. PubMed ID: 26976362
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
[TBL] [Abstract][Full Text] [Related]
19. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database.
Snydman DR; Kistler KD; Ulsh P; Bergman GE; Vensak J; Morris J
Clin Transplant; 2011; 25(4):E455-62. PubMed ID: 21504474
[TBL] [Abstract][Full Text] [Related]
20. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
